December 2018 FDA Recall Drug by Teva Pharmaceuticals Usa
D-0381-2019 - Failed dissolution specifications

This Class II drug recall was voluntarily initiated by Teva Pharmaceuticals Usa on December 19, 2018 for the product Drug. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0381-2019

Reason for Recall
Failed dissolution specifications
Initiated
12-19-2018
Reported
01-23-2019
Quantity
181,456 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Teva Pharmaceuticals USA
Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 40 mg/25 mg, packaged in a) 30-count bottle (NDC 0093-7617-56), b) 90-count bottle (NDC 0093-7617-98), Rx only, Manufactured In Israel By: Teva Pharmaceutical, IND. LTD., Jerusalem, 9777402, Israel, Manufactured For: Teva Pharmaceutical USA, INC., North Wales, PA 19454

Batch or Lot Expiration Information

Lot# : a) 49O005, 49O006, 49O007, 49O010, Exp 02/2019; b) 49O005, 49O009, 49O010, Exp 02/2019